Genelux prices 3M shares at $3.50 in underwritten public offering

Genelux (GNLX) announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5M, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. The net proceeds from the offering are to be used for working capital and for general corporate purposes, including the continued clinical development of Olvi-Vec. The offering is expected to close on or about March 26, 2025, subject to customary closing conditions